Catalent, Inc. (NYSE:CTLT) Shares Bought by Polar Asset Management Partners Inc.

Polar Asset Management Partners Inc. lifted its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 5,150.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 525,000 shares of the company’s stock after buying an additional 515,000 shares during the period. Catalent makes up approximately 0.7% of Polar Asset Management Partners Inc.’s holdings, making the stock its 25th largest position. Polar Asset Management Partners Inc. owned approximately 0.29% of Catalent worth $31,799,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Brooklyn Investment Group acquired a new position in Catalent in the 3rd quarter valued at $31,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Catalent during the second quarter worth about $42,000. Sentry Investment Management LLC purchased a new position in Catalent during the third quarter worth about $53,000. Longfellow Investment Management Co. LLC lifted its position in Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after purchasing an additional 305 shares during the period. Finally, GAMMA Investing LLC boosted its holdings in Catalent by 25.9% in the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after purchasing an additional 212 shares in the last quarter.

Catalent Stock Performance

NYSE:CTLT opened at $61.72 on Wednesday. Catalent, Inc. has a twelve month low of $36.74 and a twelve month high of $62.08. The company has a market capitalization of $11.20 billion, a P/E ratio of -27.31, a price-to-earnings-growth ratio of 2.44 and a beta of 1.15. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The firm has a 50-day moving average price of $59.96 and a two-hundred day moving average price of $58.60.

Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. Catalent’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter last year, the company posted ($0.10) EPS. As a group, research analysts expect that Catalent, Inc. will post 0.84 earnings per share for the current fiscal year.

Insider Buying and Selling at Catalent

In related news, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. This trade represents a 5.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the sale, the director now owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. This represents a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,114 shares of company stock worth $305,931 in the last 90 days. 0.31% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have recently commented on CTLT shares. Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Robert W. Baird restated a “neutral” rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. William Blair reiterated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, StockNews.com raised shares of Catalent from a “sell” rating to a “hold” rating in a report on Monday. Eight equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $63.40.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.